Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a fixed-dose combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (H. pylori).
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Standard Regimen:** One Sachet twice daily for 7 days. Each sachet contains pantoprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg.
* **Note:** Dosing may vary based on local resistance patterns and specific patient factors.
## Pediatric Dosing
* There is **no established pediatric dosing** for Sompraz HP.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is provided for the combination product. However, amoxicillin and clarithromycin may require adjustment in severe renal impairment. Pantoprazole generally does not require dose adjustment in renal impairment.
* **Hepatic Impairment:** No specific dose adjustment is provided. Use with caution.
## Contraindications
* Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of allergic reactions to penicillins or cephalosporins.
* Concomitant use with cisapride, ergotamines, midazolam, pimozide, or lovastatin/simvastatin.
* Severe hepatic impairment.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, taste perversion, headache, rash.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), liver dysfunction (including cholestasis and hepatitis), QT prolongation (with clarithromycin).
## Key Drug Interactions
* **Clarithromycin:**
* CYP3A4 inhibitors/inducers (e.g., statins, certain antifungals, antiretrovirals, anticonvulsants).
* Colchicine.
* Theophylline.
* Warfarin.
* **Pantoprazole:**
* Drugs whose absorption is pH-dependent (e.g., ketoconazole, itraconazole, iron salts, vitamin B12).
* Methotrexate.
* Potentially affects other CYP enzyme substrates (though less significant than some other PPIs).
* **Amoxicillin:**
* Allopurinol (increased risk of rash).
* Probenecid.
* Oral contraceptives (potential for reduced efficacy).
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for diarrhea, especially *C. difficile*-associated diarrhea.
* Monitor liver function tests if prolonged therapy or in patients with pre-existing hepatic issues.
* Assess for resolution of *H. pylori* infection (typically via urea breath test, stool antigen test, or biopsy at least 4 weeks after completion of therapy).
## Clinical Pearls
* Ensure patients complete the full 7-day course of therapy.
* If *H. pylori* is not eradicated after the first course, a second course with different antibiotics may be necessary, considering local resistance patterns.
* Advise patients to take the medication as directed, typically with food.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the official prescribing information and relevant guidelines for complete details and to ensure the safety and appropriateness of drug use. Dosing and indications can vary based on local protocols and individual patient circumstances.*
